REG - ValiRx PLC - Directorate Change

ValiRxAnnouncement

18/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240118:nRSR0665Aa&default-theme=true

RNS Number : 0665A  ValiRx PLC  18 January 2024

18 January 2024

VALIRX PLC

("ValiRx" or the "Company")

Directorate Change

ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on
early-stage cancer therapeutics and women's health, announces the resignation
of Stella Panu as a Non-Executive Director of the Company, effective from 15
April 2024.

Following the fundraise in January 2024, Stella has decided to step down from
the Board of ValiRx to concentrate on her other commitments. Stella has agreed
to a 3-month handover period to allow sufficient time for the Board to
identify an appropriate replacement and ensure a smooth transition of
responsibilities.

During Stella's tenure as a Non-Executive Director, she has made significant
contributions to the development of the strategy and the changes required to
ensure the Company achieves its longer-term growth goals. Stella's expertise
and guidance have been invaluable, and the Company would like to express its
gratitude for her dedicated service.

With Stella's support, the Company will be working diligently to identify a
suitable candidate to fill the vacancy created by her departure. In
particular, the Board will be seeking candidates with a background in
early-stage pharmaceutical development, aligning with our strategic focus.
The Board and management are committed to ensuring a seamless transition and
will work closely with Stella to facilitate a comprehensive handover of
duties.

Kevin Cox, Chairman of ValiRx commented "I would very much like to extend my
sincere appreciation to Stella for her invaluable contributions to ValiRx over
the past years. Her knowledge and skills have been instrumental in the
successful acquisition of Imagen Therapeutics assets, which have provided a
significant milestone in the development of Inaphaea Biolabs. Her presence on
the Board and guidance to me will be greatly missed, and I wish her continued
success in future endeavours."

The Directors of the Company take responsibility for this announcement.

For more information, please contact:

 

 ValiRx plc                                          Tel: +44 (0) 2476 796496

                                                     www.valirx.com (http://www.valirx.com)

 Dr Suzanne Dilly, CEO                               Suzanne.Dilly@valirx.com (mailto:Suzanne.Dilly@valirx.com)

 V Formation (Public Relations)                      +44 (0) 115 787 0206

                                                     www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                                 lucy@vformation.biz

                                                     sue@vformation.biz
 Cairn Financial Advisers LLP (Nominated Adviser)    Tel: +44 (0) 20 7213 0880

 Liam Murray/Jo Turner/Ludovico Lazzaretti

 Cavendish Capital Markets Limited (Joint Broker)    Tel: +44 (0) 20 7397 8900

 Dale Bellis/Michael Johnson (Sales)

 Callum Davidson/Giles Balleny (Corporate Finance)
 Turner Pope Investments (Joint Broker)              Tel: +44 (0) 20 3657 0050

 James Pope / Andy Thacker

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPUWAGUPCGMM